

#769/362

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Bischoff, et al.

Serial No.: National Stage Filing of PCT/EP00/08836

Filed: Herewith

For: Novel Combination for the Treatment of Sexual Dysfunction

BOX PCT
ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Susan M. Pellegrino

Susan M. Pellegrino
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Reg. No. 48,972

Telephone: (203) 812-6450

Date: MAR 13 2002

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Serial No.	Group Art Unit	Filing Date	Atty. Docket No.
						MAR 13 2002	Le A 33 965
INFORMATION DISCLOSURE CITATION				Applicant(s)	BISCHOFF, et al.		

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.	DATE MM/DD/YY	NAME	CLASS	S U B - CLASS	FILING DATE IF APPROPRIATE
---	--	--------------	------------------	------	-------	------------------	-------------------------------

	U1	5	0	0	6	5	3	0.	04/09/91	Angerbauer et al.	514	277	01/17/89

FOREIGN PATENT DOCUMENTS

*		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	S U B - CLASS	TRANSLATION	
		YES	NO											
	F1	9	9	2	4	4	3	3	20/05/99	WO				X
	F2	9	6	1	6	6	4	4	06/06/96	WO				
	F3	9	4	2	8	9	0	2	22/12/94	WO				
	F4	0	3	2	5	1	3	0	26/07/89	EP				X

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	R2	Cheitlin, M. D., Hutter, A. M., Brindis, R. G., Ganz, P., Kaul, S., Russell, R. O., Zusman, R. M., "Use of Sildenafil (Viagra) in Patients with Cardiovascular Disease", Circulation, 99: 168-177 (1999)
	R3	Laufs, U., La Fata, V., Plutzky, J., Liao, J. K., "Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors", Circulation, 97: 1129-1135 (1998)
	R4	Watanabe, M., Koike, H., Ishiba, T., Okada, T., Seo, S., Hirai, K., "Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors", Bioorganic & Medicinal Chemistry, 5(2): 437-444 (1997)

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	